I have non-valvular atrial fibrillation and have been prescribed Xarelto®▼ (rivaroxaban) to reduce my risk of stroke.

Patient information booklet

You have been prescribed Xarelto® for the prevention of stroke in non-valvular atrial fibrillation.

The following guide is for your information, and does not replace the patient information leaflet found with your medicine. If you are unsure about why you have been prescribed Xarelto, please speak to your healthcare professional.

Select your language from the drop-down menu:

Select language

How to transition from Warfarin to Xarelto?

Transitioning from warfarin to rivaroxaban is not suitable for every patient. This change to your prescription medication should only be made by your doctor after clinical assessment.

This medical information is intended specifically for UK patients transitioning from warfarin to rivaroxaban. You have decided with your doctor to transition from warfarin to a Direct Oral Anticoagulant (DOAC).

You are being treated for the prevention of stroke and systemic embolism, transitioning you from warfarin to rivaroxaban should be made when your International Normalised Ratio (INR) levels are ≤ 3.0.

You should always take your medication exactly as your doctor has advised to ensure this medication is working effectively. Please take great care not to accidentally take both warfarin and Xarelto together. Refer to the Xarelto patient information leaflet for more information.

Further information can be found in our patient booklet:

To access the latest version of the Xarelto 2.5mg, 10mg and 15/20 mg Summary of Product Characteristics (SmPC) as well as Xarelto Patient Information Leaflet (PIL), please click on the following link eMC Widget

Report Possible Side Effects

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.

You can also report side effects and quality complaints to Bayer Plc. Further information is available on the “contact” tab at www.bayer.co.uk.

By reporting side effects you can help provide more information on the safety of this medicine.